CVE:MDP Medexus Pharmaceuticals (MDP) Stock Price, News & Analysis → top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL) (From Traders Agency) (Ad) Free MDP Stock Alerts C$7.75 -0.40 (-4.91%) (As of 06/16/2021) Add Compare Share Share Today's RangeC$7.70▼C$8.1450-Day RangeC$7.75▼C$7.7552-Week RangeC$2.80▼C$9.75Volume40,981 shsAverage Volume68,619 shsMarket CapitalizationC$148.54 millionP/E RatioN/ADividend YieldN/APrice TargetC$3.18 Stock AnalysisStock Analysis Get Medexus Pharmaceuticals alerts: Email Address Medexus Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside59.0% DownsideC$3.18 Price TargetShort InterestN/ADividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingAcquiring SharesC$5,408 Bought Last QuarterProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.07 out of 5 stars 1.5 Analyst's Opinion Consensus RatingMedexus Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageMedexus Pharmaceuticals has received no research coverage in the past 90 days. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for MDP. Previous Next 0.0 Dividend Strength Dividend YieldMedexus Pharmaceuticals does not currently pay a dividend.Dividend GrowthMedexus Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for MDP. Previous Next 0.6 News and Social Media Coverage Search Interest2 people have searched for MDP on MarketBeat in the last 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Medexus Pharmaceuticals insiders have bought more of their company's stock than they have sold. Specifically, they have bought C$5,408.00 in company stock and sold C$0.00 in company stock. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Medexus Pharmaceuticals is -4.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Medexus Pharmaceuticals is -4.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Growth RatioDue to a projected decrease in earnings for Medexus Pharmaceuticals, their PEG ratio cannot be calculated.Price to Book Value per Share RatioMedexus Pharmaceuticals has a P/B Ratio of 20.50. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Traders Agencytop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.Click here now for the full details of this stock that’s set to rocket in the AI revolution… About Medexus Pharmaceuticals Stock (CVE:MDP)Medexus Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada and the United States. The company's primary products are Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with Hemophilia B; and Rupall, which is indicated for the treatment of seasonal allergic rhinitis, perennial allergic rhinitis, and chronic spontaneous urticaria in patients 2 years of age and older. Its products portfolio also include Cuvposa, which is indicated for sialorrhea in patients aged 3-18 years with neurologic conditions, such as cerebral; Gliolan, an orally administered drug used for the visualization of various brain tumors; and Treosulfan, a conditioning agent used prior to stem cell transplantation. The company was formerly known as Pediapharm Inc. and changed its name to Medexus Pharmaceuticals Inc. in December 2018. Medexus Pharmaceuticals Inc. is based in Verdun, Canada.Read More MDP Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart MDP Stock News HeadlinesFebruary 13, 2024 | au.finance.yahoo.comMedexus Pharmaceuticals Inc (P731.BE)February 10, 2024 | finance.yahoo.comMedexus Pharmaceuticals Inc. Just Reported A Surprise Loss: Here's What Analysts Think Will Happen NextApril 23, 2024 | Traders Agency (Ad)top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.January 30, 2024 | finance.yahoo.comMedexus Schedules Third Fiscal Quarter 2024 Conference CallNovember 30, 2023 | finance.yahoo.comBoasting A 23% Return On Equity, Is Medexus Pharmaceuticals Inc. (TSE:MDP) A Top Quality Stock?November 8, 2023 | finance.yahoo.comMedexus Announces Strong Fiscal Q2 2024 Results, Including Quarterly Revenue of US$30.3 MillionNovember 1, 2023 | finance.yahoo.comMedexus Schedules Second Fiscal Quarter 2024 Conference CallOctober 16, 2023 | finance.yahoo.comCanadian Investment Regulatory Organization Trading Halt - MDP.DBApril 23, 2024 | Traders Agency (Ad)top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.October 11, 2023 | finance.yahoo.comMedexus Pharmaceuticals' (TSE:MDP) earnings growth rate lags the 131% return delivered to shareholdersOctober 6, 2023 | finance.yahoo.comMedexus Announces Closing of C$10 Million Bought-Deal Public OfferingSeptember 15, 2023 | finance.yahoo.comShareholders May Be More Conservative With Medexus Pharmaceuticals Inc.'s (TSE:MDP) CEO Compensation For NowAugust 31, 2023 | msn.comMedexus Pharmaceuticals (MEDXF) Price Target Increased by 16.36% to 3.18August 23, 2023 | theglobeandmail.comClosing Bell: Medexus Pharmaceuticals Inc up on Wednesday (MDP)August 19, 2023 | finance.yahoo.comHere's Why We Think Medexus Pharmaceuticals (TSE:MDP) Is Well Worth WatchingJuly 13, 2023 | markets.businessinsider.comMedexus Pharmaceuticals Inc (MDP) Gets a Buy Rating from Stifel NicolausJune 22, 2023 | markets.businessinsider.comMedexus Pharmaceuticals Inc (MDP) Receives a Buy from Echelon Wealth PartnersJune 21, 2023 | finanznachrichten.deMedexus Pharmaceuticals Inc.: Medexus Generates Record Revenue of Us$108.1 Million in Fiscal Year 2023June 21, 2023 | finance.yahoo.comMedexus Generates Record Revenue of US$108.1 Million in Fiscal Year 2023June 13, 2023 | finance.yahoo.comMedexus Highlights Data on Trecondyv (Treosulfan) Presented at MDS 2023May 9, 2023 | finance.yahoo.comMedexus Demonstrates Cost-Effectiveness of Gleolan-Guided Surgery for High-Grade GliomaMay 3, 2023 | theglobeandmail.comClosing Bell: Medexus Pharmaceuticals Inc down on Tuesday (MDP)April 18, 2023 | finance.yahoo.comMedexus to Participate in the 2023 Bloom Burton & Co. Healthcare Investor ConferenceApril 14, 2023 | theglobeandmail.comClosing Bell: Medexus Pharmaceuticals Inc down on Thursday (MDP)April 13, 2023 | theglobeandmail.comClosing Bell: Medexus Pharmaceuticals Inc down on Wednesday (MDP)April 12, 2023 | theglobeandmail.comClosing Bell: Medexus Pharmaceuticals Inc up on Tuesday (MDP)April 7, 2023 | theglobeandmail.comClosing Bell: Medexus Pharmaceuticals Inc up on Thursday (MDP)See More Headlines Receive MDP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Medexus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeCVE SectorMedical Industry Drug Manufacturers - Specialty & Generic Sub-IndustryN/A Current SymbolCVE:MDP CUSIPN/A CIKN/A Webwww.medexus.com Phone514-762-2626FaxN/AEmployeesN/AYear FoundedN/APrice Target and Rating Average Stock Price TargetC$3.18 High Stock Price TargetC$4.00 Low Stock Price TargetC$2.35 Potential Upside/Downside-59.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E Ratio9.23 P/E Growth-2153Net IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity Ratio1,174.36 Current Ratio1.19 Quick Ratio0.74 Sales & Book Value Annual SalesC$108.29 million Price / Sales1.37 Cash FlowC$0.62 per share Price / Cash Flow12.46 Book ValueC$0.38 per share Price / Book20.50Miscellaneous Outstanding Shares19,167,000Free FloatN/AMarket CapC$148.54 million OptionableNot Optionable BetaN/A Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report Key ExecutivesMr. Kenneth d'EntremontCEO & DirectorMr. Roland BoivinChief Financial OfficerMr. Bill PoncySr. VP of Commercial Operations - United StatesMr. Brian PetersVP of Sales & Marketing - United StatesMs. Tina Byers CFAExec. of Investor RelationsMr. Michael PineSr. VP of Bus. Devel. & StrategyMr. Michael David Adelman (Age 50)Gen. Mang., U.S. Operations More ExecutivesKey CompetitorsHLS TherapeuticsTSE:HLSCardiol TherapeuticsTSE:CRDLBioSyentCVE:RXLeaf MobileTSE:LEAFGreen Organic DutchmanTSE:TGODView All CompetitorsInsidersBenoit GravelBought 3,200 shares on 2/13/2024Total: C$5,408.00 ($1.69/share) MDP Stock Analysis - Frequently Asked Questions Should I buy or sell Medexus Pharmaceuticals stock right now? 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Medexus Pharmaceuticals in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" MDP shares. View MDP analyst ratings or view top-rated stocks. What is Medexus Pharmaceuticals' stock price target for 2024? 2 brokerages have issued 1 year price targets for Medexus Pharmaceuticals' shares. Their MDP share price targets range from C$2.35 to C$4.00. On average, they expect the company's share price to reach C$3.18 in the next twelve months. This suggests that the stock has a possible downside of 59.0%. View analysts price targets for MDP or view top-rated stocks among Wall Street analysts. How have MDP shares performed in 2024? Medexus Pharmaceuticals' stock was trading at C$7.75 on January 1st, 2024. Since then, MDP shares have increased by 0.0% and is now trading at C$7.75. View the best growth stocks for 2024 here. What other stocks do shareholders of Medexus Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Medexus Pharmaceuticals investors own include Gatekeeper Systems (GSI), Enghouse Systems (ENGH), Ag Growth International (AFN). How do I buy shares of Medexus Pharmaceuticals? Shares of MDP stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.Compare Top Brokerages Here. This page (CVE:MDP) was last updated on 4/23/2024 by MarketBeat.com Staff From Our PartnersThe A.I. story nobody is telling you (Read ASAP)TradeSmithHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportThis Apple-like Innovator is Revolutionizing HealthcareWall Street Startop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingUrgent Alert: Biden's IRS Targeting Your Money – Act Fast to Protect It!American AlternativeDid You Get Your Free Bitcoin Yet?Crypto Swap Profits[Shocking] Elon Musk’s Plan To End BanksCrypto 101 Media Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Medexus Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
